IMPORTANCE Cannabis use during adolescence is known to increase the risk for schizophrenia in men. Sex differences in the dynamics of brain maturation during adolescence may be of particular importance with regard to vulnerability of the male brain to cannabis exposure.
C annabis is the most common illicit substance used across the world, with the 2012 annual prevalence of cannabis use reaching 3.8% (177.63 million users) among people aged 15 to 64 years. 1 Globally, more than 13 million people were dependent on cannabis in 2010; annual prevalence of cannabis dependence appears to peak between 20 and 24 years of age and is higher in males than females and in high-income countries. 2 Adolescence is a period of transition that involves a large number of age-related changes in physiological processes (eg, sex hormones) and social environment (eg, peerpeer interactions). 5, 6 Such influences-often in interaction with genetic variations-shape the neurobiological features that underly maturation of the adolescent brain, as quantified in vivo with magnetic resonance imaging (MRI). A number of large-scale MRI studies of typically developing adolescents [7] [8] [9] [10] [11] [12] have identified age-related changes in gray and white matter volumes, cortical thickness, white-matter microstructure, and brain response to various stimuli and cognitive processes. Many of these brain metrics show sex differences in their trajectories, such as steeper slopes of age-related increases in white matter and decreases in (cortical) gray matter in male compared with female adolescents. 13, 14 These sex differences in the dynamics of brain maturation during adolescence may be of particular importance with regard to vulnerability of the male brain to external factors, such as cannabis exposure, during this period of development. In this context, we note previous observations of an earlier onset of schizophrenia in men compared with women; the first signs of schizophrenia, the first positive symptoms, and the first admissions occur 3 to 5 years earlier in men, and the age range of the first sign of mental disorder is from 15 to 24 years for men (compared with 20-29 years for women). 15 Given the solid epidemiologic evidence supporting a link between cannabis exposure during adolescence and schizophrenia, 16 we investigate whether the use of cannabis during early adolescence (by 16 years of age) is associated with variations in brain maturation as a function of genetic risk for schizophrenia, as assessed with the recently developed polygenic risk score. 17 We address this question in 3 samples of typically developing youth for whom we have obtained (1) information about their cannabis use during adolescence; (2) structural T1-weighted MRI of the brain; and (3) their polygenic risk score for schizophrenia. 17 
Methods

Samples and Overall Strategy
The initial analysis was performed in a sample of 1024 adolescents recruited in the context of the Saguenay Youth Study (SYS). 18 This sample comes from the Saguenay Lac-Saint- Given the known sex differences in brain maturation during adolescence, we performed all analyses (SYS and IMAGEN samples) for male and female adolescents separately; in the ALSPAC sample, MRIs were available in male participants only. The institutional review boards of all participating institutions approved all studies reported herein. The parents and adolescents provided written informed consent and assent, respectively. All data were deidentified. In all samples, we used exposure to cannabis by 16 years of age as the main independent variable; this choice is consistent with the epidemiologic findings on cannabis use during adolescence, with the high dynamics of brain development in early to middle adolescence, and with the previous work on the association between cannabis use by 16 years of age and structural properties of the adolescent 22 and adult 23,24 brains.
In the SYS sample, we classified adolescents as having ever or never used cannabis based on their answer to a question about lifetime cannabis use; information about the number of occasions of cannabis use in their lives was not available. In the ALSPAC and IMAGEN samples, we were able to address the latter question using (ordinal) data on the number of occasions of cannabis use by 16 years of age. We used the mean cortical thickness (across the entire cortical mantle) as the main dependent variable. We believe that cortical thickness is a useful metric for capturing the cumulative effects of various experiential factors on cortical neurobiological features, especially neuropil (ie, dendrites, glial cells) and capillary densities. 25 In addition to the mean thick- 
Statistical Analysis
All statistical analyses were performed with JMP (version 17 10.0; SAS Institute Inc). Effect sizes were calculated using R software (version 3.1.2). 27 Linear regression was the primary statistical test used. The Cohen d statistic, Pearson correlation, Spearman correlation, and t tests were also used as specified in the Results section below and in the eResults in the Supplement.
Results
SYS Sample
In male adolescents (459 with available data) in the SYS sample, we observed an interaction between cannabis use (never/ ever) and the risk score on age-adjusted cortical thickness (t 455 = −2.60; P = .009); as shown in Figure 1A , age-adjusted cortical thickness decreases with the increasing risk score in cannabis users (R 2 = 0.06; P = .002) but not in nonusers (R 2 = 8.4 × 10 −5 , P = .87). We observed main effects of cannabis use (t 455 = −2.69; P = .008) but not the risk score (t 455 = 0.16; P = .87). As expected, those who ever used cannabis were older than those who never used cannabis, but this relationship does not vary between participants with low and high polygenic scores (P = .59, logistic regression). Figure 1B shows the differences in thickness across risk score deciles and cannabis use in male adolescents; Figure 1C shows the interaction between cannabis use and risk score on age-adjusted cortical thickness in female adolescents. Results of a vertex-based analysis of the interaction between Schizophrenia Risk Score and cannabis groups (ever vs never) vis-à-vis cortical thickness are shown in eTable 2 in the Supplement.
The above results are comparable to those obtained when using sex-specific median values of the risk score to classify adolescents in the high (ie, above the median) and low (below the median) risk groups. We use this strategy in the ALSPAC and IMAGEN samples to evaluate the possible effects of cumulative cannabis frequency, given the small number of individuals in the different cannabis frequency cells. To allow a comparison of the 3 samples using this approach, we have reanalyzed the SYS data using the median-based risk groups ( Figure 2A and eFigure and eResults in the Supplement).
IMAGEN Sample
In the IMAGEN sample of adolescents (145 male and 188 female participants with available data), we were able to evaluate a relationship between frequency of cannabis use (by 16 years of age) and change in cortical thickness during adolescence (from time 1 [approximately 14.5 years] to time 2 [approximately 18.5 years] adjusted for scanner manufacturer). We observed an interaction between cannabis use (never/ever) and the risk score on the adjusted change in cortical thickness (t 137 = −2.36; P = .02). In this model, we also observed main effects of cannabis use (t 137 = −2.29; P = .02) and risk score (t 137 = 2.76; P = .007). In female participants, we observed a main effect of risk score (t 181 = −2.75; P = .007) but not of cannabis use (t 181 = 0.90; P = .37) or the interaction between them (t 181 = 1.36; P = .18). We were able to evaluate a relationship between frequency of cannabis use (by 16 years of age) and change in cortical thickness using the medianbased groups ( Figure 2C and eFigure and eResults in the Supplement).
ALSPAC Sample
In this sample of male youth (295 with available data), we were able to evaluate again a relationship between the frequency of cannabis use (by 16 years of age) and age-adjusted cortical thickness measured from 18 to 21 years of age. First, we found no difference in cortical thickness between those who never and those who ever used cannabis, with the latter consisting of those who reported cannabis use with any frequency, in the high-risk (P = .78) and in the low-risk (P = .61) groups. Second, using the median-split approach ( Figure 2C ), we observed a difference in the high-risk group in age-adjusted cortical thickness (in arbitrary units) between those who never used cannabis and the most frequent users (ie, ≥61 occasions), with a difference of 0.07 (95% CI, 0.01-0.12; P = .02; Cohen d = 0.8). We also observed a similar difference between light users (<5 occasions) and the most frequent users (difference, 0.11 [95% CI, 0.03-0.18]; P = .004; d = 1.9). No such differences were observed in the low-risk group.
Relationship Between Cannabis-Related Differences in Thickness and CNR1 Expression
Expression of CNR1 varies across the 34 cortical regions segmented by FreeSurfer 28 ; as shown in Figure 3A , these regional variations are consistent across the 6 donors for whom expression data were available (left hemisphere). Figure 3B depicts group differences between those who never and ever used cannabis (SYS male participants) as a function of CNR1 expression (eTable 3 in the Supplement). We observed high rankorder correlations between the group difference in cortical The SYS participants are stratified by cannabis use as never and ever having used. A, Among SYS male participants, 317 had never and 142 had ever used cannabis. Regression lines for those who never and ever used are plotted with shaded 95% CIs. Median risk score is marked with the dotted vertical line. Risk scores range from −1.86 to 1.53, with greater scores indicating higher risk. B, Dot plots show age-adjusted cortical thickness across risk score deciles of male adolescents who never and ever used cannabis. Mean thickness values are marked with solid bars. The Schizophrenia Working Group of the Psychiatric Genomics Consortium 17 found that the top decile (based on the top 108 loci) contained about 3 times more cases of schizophrenia than the bottom decile (mean odds ratio across 39 samples, 3.21). C, Among SYS female participants, 319 had never and 171 had ever used cannabis. A weak albeit significant relationship between cortical thickness and risk score is seen with cannabis exposure. Lines and risk scores are described in part A. Cortical thickness is presented in arbitrary units (residuals).
Genetic Risk for Schizophrenia and Cortical Thickness
Original thickness and CNR1 expression across the 34 regions in the low-risk (Figure 3B , left; ρ = −0.64; P = 7.6 × 10 −5 ) and highrisk (Figure 3B , right; ρ = −0.48; P = .005) male SYS participants. Thus, the largest group differences between those who never and ever used cannabis were found in regions that showed high CNR1 expression (eg, entorhinal and anterior cingulate cortex).
Discussion
Across 3 population-based samples of typically developing youth, we observed a negative association between cannabis use in early adolescence and cortical thickness in male adolescents with a high genetic risk for schizophrenia, as indicated by their risk profiles across 108 genetic loci identified by the Psychiatric Genomics Consortium in a large genomewide comparison of patients with schizophrenia and control individuals. 17 This association appears to vary with the cumulative frequency of cannabis use before 16 years of age, as evaluated in two of the samples. The association may emerge during adolescence, as evidenced by the longitudinal MRI data obtained in one of the samples. Male participants with low polygenic risk scores and all female participants did not present similar associations in our data sets. Observational studies such as ours cannot attribute causality to the observed relationships. Even the longitudinal design does not rule out the possibility that individuals with a particular developmental trajectory may be more likely to experiment with cannabis rather than the cannabis exposure affecting the trajectory. Although genetic approaches, such as mendelian randomization, 29 may address this issue to some extent, only studies in model systems allow one to assess the true consequences of cannabis exposure in organisms randomized experimentally into different treatments. Unlike the SYS and IMAGEN samples, the high-risk male participants in the ALSPAC sample do not show a difference in cortical thickness between those who never and ever used cannabis; only the high-frequency users do. We can only speculate that, with a given sample size, the association between lessfrequent cannabis use and cortical thickness is less robust and, therefore, sensitive to other (confounding) effects that may accumulate with age; the ALSPAC sample is almost 5 years older than the SYS sample.
Adolescence is a period of vulnerability with regard to the emergence of psychotic disorders, 30 perhaps especially in boys. 15 Cannabis use during adolescence may be a contributing factor; high odds ratios were found for schizophrenia in a 35-year prospective study of men 16 when the investigators compared frequent cannabis users (>50 occasions by those aged 18-19 years) with nonusers. Our findings suggest that cannabis use might interfere with the maturation of the cerebral cortex in male adolescents at high risk for schizophrenia by virtue of their polygenic risk score. The overall volume of cortical gray matter and cortical thickness decrease with age in typically developing male adolescents. 13, 14 Our longitudinal findings suggest that cannabis exposure might accelerate such processes, including cortical thinning, in male adolescents with a high polygenic risk score. A profound thinning of cortical gray matter was observed during adolescence in patients with childhood-onset schizophrenia (onset of symptoms by 12 years of age) 31,32 and, to a much lesser extent, in their nonpsychotic siblings. 33 Patients with childhood-onset schizophrenia have higher polygenic risk scores for schizophrenia than their siblings. 34 Several studies suggest that associations between cannabis use and various outcomes may be particularly pronounced during early (<16 years) adolescence. [35] [36] [37] [38] Follow-up observations of the adolescents in the SYS and IMAGEN samples will allow us to evaluate whether this association applies for those who initiate the use of cannabis during late adolescence.
What might underlie cannabis-related thinning of cerebral cortex in male adolescents? In general, the following 2 processes may play a key role in shaping cortical thickness during male adolescence: (1) experience-driven plasticity and related growth of neuropil, which increases cortical thickness over time; and (2) testosterone-induced restructuring of neuropil, which decreases cortical thickness over time.
The first process, namely, experience-related plasticity, has been shown to drive changes in brain structure, as measured with MRI.
39,40 Cannabis may interfere with this process at pharmacologic and psychosocial levels. The former possibility is supported by the role of cannabinoid type 1 receptors in longterm potentiation [41] [42] [43] and in various neurotrophic events.
44
Chronic exposure to cannabis is associated with lower plasma levels of neurotrophins, such as brain-derived neurotrophic factor 45 and nerve growth factor. 46 The latter possibility is supported by studies suggesting that cannabis use during adolescence is associated with a number of psychosocial phenomena that may limit the richness of educational (eg, dropping out of high school [47] [48] [49] ) and extracurricural (eg, lower engagement in sports 50 ) experiences during this period of development. These pharmacologic and psychosocial pathways together may attenuate over time experience-related increases in cortical thickness during adolescence. The second process, namely, testosterone-driven variations in cortical gray matter, has been demonstrated in a number of MRI studies of typically developing male adolescents. 13 In this report, the polygenic risk score for schizophrenia calculated with the genome-wide significant SNPs (P < 5 × 10 −8 ) showed an association with cortical thickness. This association was not in evidence when we calculated the score with the 24 727 nominally significant SNPs (P < .05) (eTable 4 in the Supplement). Nevertheless, the latter score is superior to the former in predicting liability to schizophrenia. 17 This discrepancy may be owing to the fact that our study examines the relationship of the polygenic risk score with a brain phenotype (cortical thickness) rather than a liability to schizophrenia. This phenotype may represent a vulnerability trait that is not specific to a particular psychiatric disorder. Similarly, genes have pleiotropic effects on psychopathologic features. 60 Herein we show that cortical thickness (in male cannabis users) is related only to a risk score based on genetic variations most strongly associated with schizophrenia, possibly by virtue of their involvement in relevant biological pathways (see below). We speculate that the top SNPs relate to brain vulnerability (a first "hit" 61 ), whereas the nominal SNPs contribute to a broad array of factors underlying heritability of specific clinical manifestations (disorders), such as schizophrenia.
With this evidence, we speculate that the moderating influence of cannabis use on the association between the genetic risk for schizophrenia and cortical thickness may represent a combination of reduced experience-related brain plasticity taking place on the background of testosteroneassociated decreases in cortical gray matter. The absence of the latter in female adolescents may represent a brain reserve that protects them to a certain extent ( Figure 1C) . The fact that the group differences in regional cortical thickness between those who never and ever used cannabis show a gradient as a function of the regional differences in CNR1 expression in the same set of cortical regions suggests that the above influences indeed interact with the cannabinoid system. Nonetheless, only experimental studies can confirm the causal role of the above molecular pathways in mediating the observed statistical relationships.
Conclusions
Cannabis use in early adolescence moderates the association between the genetic risk for schizophrenia and cortical maturation among male individuals. This finding implicates processes underlying cortical maturation in mediating the link between cannabis use and liability to schizophrenia. 
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